menu
    • menu
    [{"orgOrder":0,"company":"Grunenthal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Grunenthal \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Grunenthal \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Shionogi"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grunenthal \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Grunenthal \/ Teva Pharmaceutical Industries"}]

    Find Musculoskeletal Clinical Drug Pipeline Developments & Deals by Grunenthal

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Grunenthal

                            Germany arrow
                            Arvo
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiniferatoxin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Grünenthal Starts Phase III Trials for Resiniferatoxin in Osteoarthritis-Related Pain

                            Details : RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.

                            Product Name : RTX

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 18, 2022

                            Lead Product(s) : Resiniferatoxin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Grunenthal

                            Germany arrow
                            Arvo
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiniferatoxin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Shionogi

                            Deal Size : $670.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Grünenthal to License Osteoarthritis Pain Treatment to Shionogi in Japan in Deal of up to > $ 500 Million

                            Details : The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX (resiniferatoxin) to Shionogi will be carried out exclusively by Grünenthal.

                            Product Name : RTX

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 08, 2022

                            Lead Product(s) : Resiniferatoxin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Shionogi

                            Deal Size : $670.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Grunenthal

                            Germany arrow
                            Arvo
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Grünenthal Closes a Deal with Teva to Market Teriparatide

                            Details : Grünenthal and Teva have reached an exclusive agreement for the marketing, distribution, and promotion of teriparatide (Tetridar) in the Spanish market.

                            Product Name : Tetridar

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            September 18, 2020

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth